HK1164837A1 - Polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-3-[5-(2-morpholin-4- yl-ethoxy)-pyrimidin-2-yl]-benzyl-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof 6-(1--1h--4-)-2-3-[5-(2--4--)--2-]--2h- -3- - Google Patents

Polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-3-[5-(2-morpholin-4- yl-ethoxy)-pyrimidin-2-yl]-benzyl-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof 6-(1--1h--4-)-2-3-[5-(2--4--)--2-]--2h- -3-

Info

Publication number
HK1164837A1
HK1164837A1 HK12105184.1A HK12105184A HK1164837A1 HK 1164837 A1 HK1164837 A1 HK 1164837A1 HK 12105184 A HK12105184 A HK 12105184A HK 1164837 A1 HK1164837 A1 HK 1164837A1
Authority
HK
Hong Kong
Prior art keywords
dihydrogenphosphate
pyridazin
morpholin
pyrazol
pyrimidin
Prior art date
Application number
HK12105184.1A
Other languages
English (en)
Chinese (zh)
Inventor
Axel Becker
Clemens Kuehn
Christoph Saal
Oliver Schadt
Dieter Dorsch
Eva Kriegbaum
Frank Stieber
Cristina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1164837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1164837A1 publication Critical patent/HK1164837A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK12105184.1A 2008-12-22 2012-05-28 Polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-3-[5-(2-morpholin-4- yl-ethoxy)-pyrimidin-2-yl]-benzyl-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof 6-(1--1h--4-)-2-3-[5-(2--4--)--2-]--2h- -3- HK1164837A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22
PCT/EP2009/008358 WO2010072295A1 (en) 2008-12-22 2009-11-24 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof

Publications (1)

Publication Number Publication Date
HK1164837A1 true HK1164837A1 (en) 2012-09-28

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105184.1A HK1164837A1 (en) 2008-12-22 2012-05-28 Polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-3-[5-(2-morpholin-4- yl-ethoxy)-pyrimidin-2-yl]-benzyl-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof 6-(1--1h--4-)-2-3-[5-(2--4--)--2-]--2h- -3-

Country Status (32)

Country Link
US (1) US8586599B2 (es)
EP (1) EP2361250B1 (es)
JP (2) JP5690741B2 (es)
KR (1) KR101663335B1 (es)
CN (1) CN102264729B (es)
AR (1) AR074686A1 (es)
AU (1) AU2009331990B2 (es)
BR (1) BRPI0923480B8 (es)
CA (1) CA2748218C (es)
CL (1) CL2011001278A1 (es)
CO (1) CO6331435A2 (es)
CY (1) CY1114659T1 (es)
DK (1) DK2361250T3 (es)
EA (1) EA019320B1 (es)
EC (1) ECSP11011219A (es)
ES (1) ES2434247T3 (es)
HK (1) HK1164837A1 (es)
HR (1) HRP20130993T1 (es)
IL (1) IL213647A (es)
MX (1) MX2011006682A (es)
MY (1) MY160526A (es)
NZ (1) NZ594172A (es)
PE (1) PE20120016A1 (es)
PL (1) PL2361250T3 (es)
PT (1) PT2361250E (es)
SG (1) SG172128A1 (es)
SI (1) SI2361250T1 (es)
SM (1) SMT201300133B (es)
TW (1) TWI448463B (es)
UA (1) UA103646C2 (es)
WO (1) WO2010072295A1 (es)
ZA (1) ZA201105394B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN111465602B (zh) 2017-10-17 2023-05-23 帕劳制药有限公司 4-氨基嘧啶化合物的合成

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
SK1862004A3 (en) 2001-10-31 2004-08-03 Type 4 phosphodiesterase inhibitors and uses thereof
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
WO2005004607A1 (en) 2003-07-02 2005-01-20 Sugen, Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
BRPI0620292B1 (pt) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PE20091079A1 (es) 2007-10-16 2009-08-24 Novartis Ag Compuestos heterociclicos como moduladores npy y2
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
MX2010004705A (es) 2007-10-31 2010-05-27 Nissan Chemical Ind Ltd Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
CA2704628C (en) 2007-11-16 2016-11-29 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
JP5395808B2 (ja) 2007-12-21 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー オレキシン受容体アンタゴニストとしてのヘテロアリール誘導体
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
EP2242483B1 (en) 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
AU2008340422B2 (en) 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ES2430210T3 (es) 2007-12-21 2013-11-19 Palau Pharma, S.A. Derivados de 4-aminopirimidina como antagonistas del receptor de histamina H4
US8003649B2 (en) 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US20120028988A1 (en) 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
CN102264729A (zh) 2011-11-30
CL2011001278A1 (es) 2011-09-30
NZ594172A (en) 2013-04-26
JP5690741B2 (ja) 2015-03-25
CN102264729B (zh) 2014-03-05
EP2361250B1 (en) 2013-08-07
SG172128A1 (en) 2011-07-28
US8586599B2 (en) 2013-11-19
UA103646C2 (ru) 2013-11-11
JP5860125B2 (ja) 2016-02-16
DK2361250T3 (da) 2013-11-04
US20110257180A1 (en) 2011-10-20
IL213647A0 (en) 2011-07-31
JP2015028093A (ja) 2015-02-12
IL213647A (en) 2013-11-28
EA019320B1 (ru) 2014-02-28
AR074686A1 (es) 2011-02-02
PE20120016A1 (es) 2012-01-24
BRPI0923480A2 (pt) 2016-08-09
ZA201105394B (en) 2012-03-28
KR101663335B1 (ko) 2016-10-06
CA2748218A1 (en) 2010-07-01
MY160526A (en) 2017-03-15
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11
SI2361250T1 (sl) 2013-12-31
EA201100973A1 (ru) 2012-01-30
MX2011006682A (es) 2011-07-13
HRP20130993T1 (hr) 2013-11-22
CA2748218C (en) 2017-08-29
SMT201300133B (it) 2014-03-07
ECSP11011219A (es) 2011-12-30
PL2361250T3 (pl) 2014-01-31
ES2434247T3 (es) 2013-12-16
JP2012513417A (ja) 2012-06-14
EP2361250A1 (en) 2011-08-31
WO2010072295A1 (en) 2010-07-01
TW201028409A (en) 2010-08-01
TWI448463B (zh) 2014-08-11
BRPI0923480B1 (pt) 2020-10-13
CY1114659T1 (el) 2016-10-05
AU2009331990B2 (en) 2016-04-14
AU2009331990A1 (en) 2011-08-11
CO6331435A2 (es) 2011-10-20
BRPI0923480B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ZA201308527B (en) Forms of rifaximin and uses thereof
HRP20150477T1 (en) Methods of preparing quinazolinone derivatives
EP2353174A4 (en) METHOD FOR PRODUCING SUBSTRATES
EP2353173A4 (en) METHODS OF MANUFACTURING SUBSTRATES
IL207609A0 (en) Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
EP2353175A4 (en) METHODS OF MANUFACTURING SUBSTRATES
IL209855A0 (en) Supression of neuroedocrine diseases
EP2357091A4 (en) EXTERNAL PART AND MANUFACTURING METHOD THEREFOR
PL2743055T3 (pl) Sposób wytwarzania wyrobu
ZA201107357B (en) Novel compounds of reverse-turn mimetics, method for manufacturing the same and use therof
TWI370517B (en) Methods of forming through substrate interconnects
HK1172328A1 (zh) 取代的嘌呤和吡唑並嘧啶化合物、組合物和使用方法
ZA201108655B (en) Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
HK1164837A1 (en) Polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-3-[5-(2-morpholin-4- yl-ethoxy)-pyrimidin-2-yl]-benzyl-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof 6-(1--1h--4-)-2-3-[5-(2--4--)--2-]--2h- -3-
EP2247531A4 (en) SILICA REDUCTION
HRP20130647T1 (en) Novel composition for treatment of essential thrombocythemia
GB0720958D0 (en) Method of manufacturing an article
PL385805A1 (pl) Sposób wytwarzania imatinibu
TWI373091B (en) Fabricating method of substrate
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
PL385350A1 (pl) Sposób wykonania modułu posadzkowego i moduł posadzki wytworzony tym sposobem
GB0803748D0 (en) Ihibitors of p38 MAP kinase
IL210360A0 (en) Vehicle and method of controlling thereof
GB0720504D0 (en) Manufacture of foamable elements

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171124